Abstract
Purpose
The G1-S checkpoint of the cell cycle is frequently dysregulated in breast cancer. Palbociclib (PD0332991) is an oral inhibitor of CDK4/6. Based upon preclinical/phase I activity, we performed a phase II, single-arm trial of palbociclib in advanced breast cancer.Experimental design
Eligible patients had histologically confirmed, metastatic breast cancer positive for retinoblastoma (Rb) protein and measureable disease. Palbociclib was given at 125 mg orally on days 1 to 21 of a 28-day cycle. Primary objectives were tumor response and tolerability. Secondary objectives included progression-free survival (PFS) and assessment of Rb expression/localization, KI-67, p16 loss, and CCND1 amplification.Results
Thirty-seven patients were enrolled; 84% hormone-receptor (HR)(+)/Her2(-), 5% HR(+)/Her2(+), and 11% HR(-)/Her2(-), with a median of 2 prior cytotoxic regimens. Two patients had partial response (PR) and 5 had stable disease ≥ 6 months for a clinical benefit rate (CBR = PR + 6moSD) of 19% overall, 21% in HR(+), and 29% in HR(+)/Her2(-) who had progressed through ≥2 prior lines of hormonal therapy. Median PFS overall was 3.7 months [95% confidence interval (CI), 1.9-5.1], but significantly longer for those with HR(+) versus HR(-) disease (P = 0.03) and those who had previously progressed through endocrine therapy for advanced disease (P = 0.02). Grade 3/4 toxicities included neutropenia (51%), anemia (5%), and thrombocytopenia (22%). Twenty-four percent had treatment interruption and 51% had dose reduction, all for cytopenias. No biomarker identified a sensitive tumor population.Conclusions
Single-agent palbociclib is well tolerated and active in patients with endocrine-resistant, HR(+), Rb-positive breast cancer. Cytopenias were uncomplicated and easily managed with dose reduction.Full text links
Read article at publisher's site: https://doi.org/10.1158/1078-0432.ccr-14-2258
Read article for free, from open access legal sources, via Unpaywall:
https://clincancerres.aacrjournals.org/content/clincanres/21/5/995.full.pdf
Citations & impact
Impact metrics
Citations of article over time
Alternative metrics
Article citations
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).
JCO Precis Oncol, 8:e2400418, 01 Sep 2024
Cited by: 0 articles | PMID: 39298716
Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.
Mol Cancer, 23(1):118, 03 Jun 2024
Cited by: 1 article | PMID: 38831405 | PMCID: PMC11145857
Slower CDK4 and faster CDK2 activation in the cell cycle.
Structure, 32(8):1269-1280.e2, 03 May 2024
Cited by: 1 article | PMID: 38703777
Reciprocal antagonism of PIN1-APC/CCDH1 governs mitotic protein stability and cell cycle entry.
Nat Commun, 15(1):3220, 15 Apr 2024
Cited by: 3 articles | PMID: 38622115 | PMCID: PMC11018817
A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors.
Nat Cancer, 5(7):996-1009, 05 Mar 2024
Cited by: 2 articles | PMID: 38443662 | PMCID: PMC11286358
Go to all (213) article citations
Data
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.